Alzheimer’s drug touted as gamechanger could triple risk of dying
New research reveals that lecanemab, an Alzheimer’s drug previously hailed for slowing disease progression, may increase the risk of death by 25%. The study found a tripled risk of death within a year for patients using lecanemab compared to those not on the drug.
